Eisai Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Eisai Company Limited with three other
companies in this sector in Japan:
Mitsubishi Tanabe Pharma Corp
sales of 423.98 billion Japanese Yen [US$3.99 billion]
of which 74%
was Domestic Ethical Drug),
Chugai Pharmaceutical Co Ltd
(534.20 billion Japanese Yen [US$5.03 billion]
Kyowa Hakko Kirin Company Limited
(353.38 billion Japanese Yen [US$3.33 billion]
Eisai Company Limited reported sales of ¥539.10 billion (US$5.07 billion)
March of 2017.
decrease of 1.6%
versus 2016, when the company's sales were ¥547.92 billion.
Contributing to the drop in overall sales was the 44.5% decline
in Other Business, from ¥16.16 billion to ¥8.97 billion.
There were also decreases in sales in
Pharmaceutical Business -Americans (down 4.1% to ¥117.22 billion)
Pharmaceutical Business -China (down 0.0% to ¥49.27 billion)
Pharmaceutical Business -Eama (down 8.5% to ¥37.83 billion)
However, these declines were partially offset by the increase in sales of
Pharmaceutical Business -Japan (up 9.1% to ¥291.07 billion)
Pharmaceutical Business -Asia (up 2.2% to ¥34.75 billion)